EcoDrugPlus

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSMOCG00000001235
Gene Symbol: FSHR
3 Cross references
199 Possible Orthologues:

Free Fatty Acid Receptor 1

Ensembl ID : ENSMOCG00000022880
Gene Symbol: FFAR1
1 Cross references
138 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSMOCG00000018465
Gene Symbol: FFAR2
1 Cross references
331 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSMOCG00000011544
Gene Symbol: FRK
3 Cross references
216 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSMOCG00000004658
Gene Symbol: GLA
2 Cross references
196 Possible Orthologues:

Galectin 1

Ensembl ID : ENSMOCG00000005534
Gene Symbol: LGALS1
3 Cross references
380 Possible Orthologues:

Galectin 3

Ensembl ID : ENSMOCG00000022866
Gene Symbol: LGALS3
3 Cross references
218 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha1 Subunit

Ensembl ID : ENSMOCG00000004272
Gene Symbol: GABRA1
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha2 Subunit

Ensembl ID : ENSMOCG00000018785
Gene Symbol: GABRA2
3 Cross references
253 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha3 Subunit

Ensembl ID : ENSMOCG00000002642
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha4 Subunit

Ensembl ID : ENSMOCG00000004120
Gene Symbol: GABRA4
3 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha5 Subunit

Ensembl ID : ENSMOCG00000001448
Gene Symbol: GABRA5
3 Cross references
262 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).